Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | GCGR | P47871 | 6/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.38 |
| ▸ | LCK | P06239 | 2/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.37 |
| ▸ | GIPR | P48546 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2651309 | 0.89 | DYRK1A (0.39) | PKMGCGRALDH1A1LMNAHPGD | |
| SCHEMBL2651441 | 0.89 | GCGR (0.41) | GCGRLMNACYP2D6DGAT1GIPR | |
| SCHEMBL2651260 | 0.89 | GCGR (0.41) | GCGRCYP2D6DGAT1GIPR | |
| SCHEMBL2650616 | 0.88 | GCGR (0.39) | PKMGCGRCYP2D6DGAT1GIPR | |
| SCHEMBL2651825 | 0.87 | GCG (0.43) | GCGRGIPR | |
| SCHEMBL6748244 | 0.87 | GCGR (0.45) | PKMGCGRCYP2D6GIPR | |
| SCHEMBL2651465 | 0.87 | GCGR (0.41) | PKMGCGRGIPR | |
| SCHEMBL6748278 | 0.86 | GCGR (0.41) | PKMGCGRGIPR | |
| SCHEMBL2651688 | 0.85 | GCGR (0.42) | PKMGCGRPCSK9CYP2D6GIPR | |
| SCHEMBL2653699 | 0.85 | GCGR (0.52) | PKMGCGRDGAT1GIPR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040127560-A1 | Glucagon antagonists/inverse agonists | MADSEN PETER (DK) | 2004-07-01 | — | — | US | claimed |
| US-6706744-B2 | HYPOGLYCEMIC AGENTS; ANTIDIABETIC AGENTS | NOVO NORDISK A/S (DK) | 2004-03-16 | — | — | US | claimed |
| US-20030065031-A1 | Glucagon antagonists/inverse agonists | PFIZER INC | 2003-04-03 | — | — | US | claimed |
| WO-2002040444-A1 | GLUCAGON ANTAGONISTS/INVERSE AGONISTS | NOVO NORDISK A/S (DK) | 2002-05-23 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127560-A1 | Glucagon antagonists/inverse agonists | GLP1R, GPR119, GCGR | PKM 3005/4885GCGR 3/4885ALDH1A1 4014/4885 |
| US-20030065031-A1 | Glucagon antagonists/inverse agonists | GLP1R, GPR119, GCGR | PKM 3005/4885GCGR 3/4885ALDH1A1 4014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.